ALK and non-small cell lung carcinoma: ,56 Ensartinib is a domestically developed ALK-TKI that was approved by the NMPA on November 19, 2020, for the treatment of locally advanced or metastatic ALK-positive NSCLC as a successive treatment after crizotinib or for crizotinib-intolerant patients.57